Gyre Therapeutics, Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.0K | $1.0M | — | — | $275.0K | $3.6M | $57.9M | $97.6M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $21.5M | $12.8M | $11.6M | $6.0M | $5.3M | $6.6M | $49.1M | $95.2M |
| SG&A Expense | $12.4M | $10.0M | $9.3M | $9.6M | $4.1M | $4.1M | $13.2M | $12.2M |
| Operating Income | $-33.8M | $-21.8M | $-20.4M | $-13.8M | $-7.5M | $-10.1M | $-8.1M | $-9.7M |
| Operating Margin | -563,700.0% | -2,143.6% | — | — | -2,730.5% | -278.9% | -14.1% | -10.0% |
| Interest Expense | — | — | — | $1.5M | $23.0K | $53.0K | $86.0K | $132.0K |
| Pretax Income | — | — | — | — | $-29.1M | $-46.7M | $-7.1M | $-8.5M |
| Income Tax Expense | — | — | — | — | $3.5M | $7.0K | $-101.0K | $0 |
| Net Income | $-30.1M | $-21.6M | $-16.9M | $-14.8M | $-6.6M | $-10.0M | $-7.0M | $-8.5M |
| Net Margin | -500,916.7% | -2,118.0% | — | — | -2,404.7% | -274.6% | -12.1% | -8.7% |
| EPS (Basic) | $-1.34 | $-3.73 | $-10.88 | $-25.00 | $-9.00 | $-13.65 | $-0.11 | $-0.14 |
| EPS (Diluted) | $-1.34 | $-3.73 | $-10.88 | $-25.00 | $-9.00 | $-13.65 | $-0.11 | $-0.14 |
| Shares Outstanding (Basic) | 23.9M | 12.2M | 1.6M | 1.5M | 741.9K | 67.4M | 67.0M | 63.3M |
| Shares Outstanding (Diluted) | 23.9M | 12.2M | 1.6M | 1.5M | 741.9K | 67.4M | 67.0M | 63.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |